LXRX

#2656
Lexicon Pharmaceuticals, Inc.
1.75 USD
+2.34%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.75
1.75
Intervallo Annuale
0.48
1.84
Variazione giornaliera
+2.34%
Variazione Mensile
+2.94%
Variazione di 6 mesi
+17.45%
Variazione Annuale
+230.19%
Chiusura Precedente
1.71
Apertura
1.75
Bid
Ask
Minimo
1.75
High
1.75
Volume
28
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 741.44 M
  • Employee 81
  • Founded 1995
  • CEO Lonnel Coats
  • Website www.lexpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000BQ85G2
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-8.21
Rapporto prezzo/fatturato
8.38

Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

Notizie